A statistically significant benefit was not reached for the co-primary endpoint of recurrence-free survival in patients whose whose tumors expressed PD-L1 <1%, according to results from phase III CheckMate -915.
NIH has announced it will stop issuing funding opportunities solely dedicated to animal models, but has not published any formal guidance related to the announcement, and researchers are unclear on when or whether further policy materials are to be expected.
